BioCentury | Sep 22, 2014
Product Development

Glenmark's new cancer BEAT

While bispecific antibodies have been around for two decades, their success in cancer has been stymied by poor in vivo properties and complex manufacturing processes. Indian biotech Glenmark Pharmaceuticals Ltd. is making a play in...
Items per page:
1 - 1 of 1